Infectious Disease Diagnostics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 38.5 billion
Estimated Base Value
2035 Forecast
US$ 72.3 billion
Projected Market Value
CAGR 2026–2035
6.5%
Compound Annual Growth
Largest Segment
Polymerase Chain Reaction Based Diagnostics
Fastest Growing Segment
Enzyme-Linked Immunosorbent Assay
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
22.5% market share
Key Players
Qiagen N.V.
Emerging Players
Mammoth Biosciences, Visby Medical
Market Definition & Overview
The Infectious Disease Diagnostics Market encompasses medical devices and related consumables used for the detection, identification, and characterization of pathogenic microorganisms in human samples. This market includes a wide array of diagnostic technologies, such as molecular diagnostics (e.g., PCR, sequencing), immunoassays (e.g., ELISA, rapid tests), and traditional microbiology methods (e.g., culture-based systems). These products are critical for accurate diagnosis, monitoring disease progression, guiding treatment decisions, and supporting public health surveillance initiatives across various settings like hospitals, reference laboratories, physician offices, and point-of-care locations. The market focuses on in-vitro diagnostic (IVD) solutions designed to improve patient outcomes by enabling timely and precise detection of infectious agents.
Scope
- Global geographical coverage across all regions
- Analysis by technology, product type, application, and end-user
- Covers hospital, laboratory, and point-of-care settings
- Examines historical trends, current market size, and future forecasts
Inclusions
- Molecular diagnostic tests (e.g., PCR, NAAT) for pathogens
- Immunoassay-based diagnostics and rapid diagnostic tests (RDTs)
- Automated microbiology culture and identification systems
- Next-Generation Sequencing (NGS) for infectious disease detection
- Mass spectrometry platforms for pathogen identification
- Diagnostic instruments, reagents, and consumables for IVD applications
Exclusions
- Therapeutic drugs and vaccines for infectious diseases
- General laboratory equipment not specific to infectious disease diagnosis
- Diagnostic services provided by laboratories (focus is on products)
- Purely research-use-only (RUO) products without clinical diagnostic intent
- Non-medical device based diagnostic methods or computational models
Market Size Forecast
Executive Summary
• The Infectious Disease Diagnostics market is valued at $38.5 Bn in 2025 and is forecast to reach $72.3 Bn by 2035, reflecting a robust CAGR of 6.5% as demand accelerates across every major segment and region over the ten-year outlook.
• Polymerase Chain Reaction Based Diagnostics leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 33.5%, while Emerging Areas is expanding the fastest at a 9.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 22.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• The market's competitive landscape is being fundamentally reshaped by aggressive consolidation, with major players strategically acquiring specialized platforms to achieve broader diagnostic capabilities and strengthen global market positioning.
• Breakthroughs in rapid molecular diagnostics and decentralized testing solutions are the primary growth catalysts, enhancing accessibility and accelerating early detection crucial for effective global infectious disease management.
• Divergent global regulatory pathways, particularly for novel pathogen identification and high-throughput screening, significantly influence regional market entry strategies and accelerate specialized product innovation across key economies.
• Strategic investments in localized manufacturing and diversified supply chains are paramount to building resilience against future public health crises, ensuring uninterrupted access to critical diagnostic tools worldwide.
• The accelerating adoption of multiplex syndromic panels and next-generation sequencing is transforming diagnostic algorithms, enabling comprehensive pathogen identification and driving precision medicine approaches in infectious diseases.
• Integration of AI and machine learning into diagnostic workflows is poised to revolutionize data interpretation and predictive analytics, significantly enhancing efficiency and global outbreak preparedness capabilities.
Key Market Takeaways
Critical findings and data points from this market research study.
Market Valuation
The Infectious Disease Diagnostics Market was valued at an impressive $38.5 billion in the base year.
Robust Growth Outlook
The market is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.5% over the forecast period.
Market Expansion Forecast
By the forecast year, the market is expected to reach a substantial value of $72.3 billion.
Key Market Drivers
Increasing prevalence of infectious diseases coupled with a rising global awareness for early and accurate diagnosis are significant drivers propelling market growth.
Diagnostic Tech Advancements
Continuous advancements in molecular diagnostics, immunoassay techniques, and point-of-care testing represent a notable trend fostering innovation and accessibility in the market.
Critical Global Impact
The market plays a vital role in global health, supporting disease surveillance, outbreak management, and timely treatment across various regions.
Market Dynamics
Market Trends
- Growing adoption of rapid point-of-care (POC) testing devices.
- Increasing demand for molecular diagnostics in infectious disease detection.
- Integration of artificial intelligence and machine learning in diagnostics.
- Shift towards multiplex syndromic panels for comprehensive pathogen identification.
Growth Drivers
- Rising global prevalence of infectious diseases and epidemics.
- Significant technological advancements in diagnostic platforms and assays.
- Increased awareness and demand for early disease diagnosis and treatment.
- Government funding and initiatives for infectious disease surveillance.
Restraints
- High cost of advanced diagnostic tests limits widespread adoption in many regions.
- Stringent regulatory approval processes hinder rapid market entry for new devices.
- Lack of robust healthcare infrastructure impacts accessibility in developing economies.
- Reimbursement challenges create financial barriers for innovative diagnostic solutions.
Opportunities
- Development of novel diagnostic tests for emerging and re-emerging pathogens.
- Expanding access to diagnostics in remote and low-resource settings.
- Personalized medicine approaches through advanced genetic sequencing.
- Leveraging telemedicine for remote diagnosis and infectious disease management.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Polymerase Chain Reaction Based DiagnosticsIsothermal Nucleic Acid Amplification TechniquesEnzyme-Linked Immunosorbent AssayChemiluminescence ImmunoassaysRapid Diagnostic TestsCulture & Sensitivity TestingNext-Generation SequencingMass Spectrometry |
| By Product | Reagents & KitsInstruments & AnalyzersSoftwareServices |
| By Application | Respiratory Panel TestingSexually Transmitted Infections TestingHospital Acquired Infections TestingHepatitis TestingHIV TestingTuberculosis TestingGastrointestinal Infections TestingTropical & Emerging Infectious Diseases Testing |
| By End-User | HospitalsDiagnostic Reference LaboratoriesPhysician Offices & ClinicsAcademic & Research InstitutionsPublic Health LaboratoriesHome Care SettingsBlood BanksPharmaceutical & Biotechnology Companies |
| By Sample Type | Blood SamplesUrine SamplesRespiratory SamplesStool SamplesCerebrospinal Fluid SamplesTissue SamplesSaliva SamplesOther Body Fluids & Exudates |
| By Mode | Manual AssaysSemi-Automated AssaysFully Automated Assays |
Regional Analysis
- North America is the leading region in the infectious disease diagnostics market, driven by its well-established healthcare infrastructure, high healthcare expenditure, significant R&D activities, and early adoption of advanced diagnostic technologies. This robust environment fosters innovation and market growth.
- The Asia Pacific region is projected to be the fastest-growing market, propelled by its enormous population base, increasing healthcare awareness, improving healthcare access, and rising disposable incomes. Government initiatives to enhance diagnostic capabilities further fuel this expansion.
- In Europe, a significant trend is the increasing shift towards point-of-care (POC) and decentralized testing solutions, driven by the need for rapid diagnostics and reduced turnaround times. This trend is further supported by digital integration and remote monitoring capabilities.
Asia Pacific
8.1% CAGR
$12.9 Bn
33.5% share
- Driven by large patient populations, increasing healthcare expenditure, and rising awareness of infectious diseases, this region is experiencing significant market expansion.
- Growing adoption of advanced diagnostic technologies also contributes to its leading share.
North America
6.5% CAGR
$11.2 Bn
29% share
- This mature market benefits from robust healthcare infrastructure, high diagnostic testing rates, and a strong focus on R&D for novel diagnostic solutions.
- Significant investment in personalized medicine and rapid diagnostics continues to fuel growth.
Europe
6.0% CAGR
$8.5 Bn
22% share
- With well-established healthcare systems and high adoption of advanced diagnostic tools, Europe maintains a substantial market share.
- Regulatory harmonization and a focus on public health initiatives further support market stability and gradual growth.
Latin America
7.5% CAGR
$3.1 Bn
8% share
- The market in Latin America is growing due to improving healthcare access, increasing government initiatives to combat infectious diseases, and expanding medical infrastructure.
- However, economic disparities and regulatory complexities can pose challenges.
Middle East & Africa
7.8% CAGR
$2.1 Bn
5.5% share
- This region presents a diverse market with varying levels of healthcare development, though increasing investment in healthcare infrastructure and rising awareness of infectious diseases are driving growth.
- Public health programs addressing endemic diseases also contribute to market expansion.
Emerging Areas
9.0% CAGR
$770.0 Mn
2% share
- Representing nascent and fragmented markets, these areas show high growth potential due to increasing global health initiatives, improving access to basic healthcare, and rising awareness of diagnostics in underserved populations.
- Limited infrastructure and economic constraints currently keep their share small.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $8.7 Bn | 6.8% | The U.S. remains the largest market for infectious disease diagnostics, driven by extensive R&D, high healthcare spending, and rapid adoption of advanced testing technologies. A robust regulatory framework and focus on precision medicine also fuel market growth. |
| 2 | Brazil | $731.5 Mn | 8.1% | Brazil is the largest market in South America, influenced by a significant burden of endemic infectious diseases like dengue and Zika, and a large population. Improving healthcare infrastructure and increasing investment in diagnostics are driving its expansion. |
| 3 | Germany | $1.7 Bn | 6.1% | Germany's market is robust, supported by its advanced healthcare system, strong emphasis on R&D, and high adoption rates of innovative diagnostic technologies. A focus on quality standards and precision diagnostics underpins its market position. |
| 4 | China | $8.4 Bn | 9.2% | China leads the global market, driven by its vast population, increasing healthcare expenditure, and a high prevalence of various infectious diseases. Rapid expansion of diagnostic infrastructure and strong government support for local manufacturing are key growth factors. |
| 5 | Saudi Arabia | $346.5 Mn | 8.9% | Saudi Arabia's market is expanding rapidly due to significant government investment in healthcare infrastructure and a growing demand for advanced diagnostics. Increased health tourism and focus on preventative care also contribute to market growth. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia Pacific, Saudi Arabia, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | bioMérieux S.A. | 6% | Innovate and expand its microbiology and molecular diagnostics solutions to improve patient health globally, with a strong focus on combating antimicrobial resistance. | A global leader in in vitro diagnostics, particularly in microbiology and syndromic molecular testing. | Continued expansion of the BIOFIRE syndromic panel menu and geographical reach for rapid infectious disease diagnosis. | VITEKBacT/ALERTBIOFIRE FILMARRAY+1 |
| 2 | Hologic, Inc. | 5.7% | Focus on women's health and diagnostics, providing innovative solutions that address critical health needs across the globe. | Dominant in women's health diagnostics, including cervical cancer screening and sexually transmitted infection testing. | Launching new assays for its Panther system, expanding its menu for infectious disease testing beyond women's health. | Panther SystemAptima assaysThinPrep+1 |
| 3 | QuidelOrtho Corporation | 5.4% | Leverage its broad portfolio of diagnostic solutions, from point-of-care rapid tests to high-throughput lab systems, to serve diverse diagnostic needs globally. | Formed from the merger of Quidel and Ortho Clinical Diagnostics, creating a diverse diagnostics powerhouse. | Launching the Savanna molecular platform, aiming to provide multiplex PCR results at the point of care for infectious diseases. | SofiaSavannaTriage+1 |
| 4 | DiaSorin S.p.A. | 5.1% | Invest in specialized diagnostic solutions, particularly in immunoassay and molecular diagnostics, to maintain leadership in niche areas and expand global reach. | Strong in immunodiagnostics with its LIAISON platform and has strategically expanded into molecular diagnostics. | Expanding its molecular diagnostic test menu, especially for respiratory infections, on its new MDX platforms. | LIAISON XLLIAISON XSVIBRIO+1 |
| 5 | Revvity, Inc. | 4.7% | Drive innovation in life sciences and diagnostics by providing comprehensive solutions from research to clinical applications, with a focus on precision health. | Rebranded from PerkinElmer to reflect its focus on health science solutions, divesting its Applied, Food and Enterprise Services businesses. | Launched new research reagents and instrumentation, enhancing its portfolio for advanced cellular and genomic analysis relevant to infectious disease research. | Victor NivoEnVisionJANUS G3+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (19)
bioMérieux S.A., Hologic, Inc., QuidelOrtho Corporation, DiaSorin S.p.A., Revvity, Inc., Bruker Corporation, Grifols S.A., Sysmex Corporation, Eurofins Scientific SE, Seegene Inc., SD Biosensor Inc., Fujirebio Holdings, Inc., OraSure Technologies, Inc., Tecan Group Ltd., Oxford Nanopore Technologies plc, Randox Laboratories Ltd., Novacyt SA, Accelerate Diagnostics, Inc., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
The global Infectious Disease Diagnostics market features a competitive landscape led by Qiagen N.V., bioMérieux S.A., Hologic, Inc., QuidelOrtho Corporation, DiaSorin S.p.A., and Revvity, Inc., among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
bioMérieux S.A.
Hologic, Inc.
QuidelOrtho Corporation
DiaSorin S.p.A.
Revvity, Inc.
Bruker Corporation
Grifols S.A.
Sysmex Corporation
Eurofins Scientific SE
Seegene Inc.
SD Biosensor Inc.
Fujirebio Holdings, Inc.
OraSure Technologies, Inc.
Tecan Group Ltd.
Oxford Nanopore Technologies plc
Randox Laboratories Ltd.
Novacyt SA
Accelerate Diagnostics, Inc.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Mammoth Biosciences
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
QuidelOrtho's Savanna Platform Gains Key Regulatory Clearances for Multiplex Diagnostics
QuidelOrtho announced the receipt of CE Mark and FDA clearance for its Savanna multiplex molecular platform and associated respiratory panels, including COVID-19, Flu A/B, and RSV. This compact, rapid point-of-care system is poised to significantly enhance diagnostic capabilities in various healthcare settings.
QIAGEN Expands Sepsis Diagnostics with New QIAstat-Dx Panel Launch
QIAGEN launched its QIAstat-Dx Blood Culture Identification (BCID) panel, providing rapid detection of common pathogens and antibiotic resistance markers directly from positive blood cultures, crucial for timely sepsis management. This enhances the company's syndromic testing portfolio for critical infections.
T2 Biosystems Secures FDA Clearance for T2 Biothreat Panel
T2 Biosystems announced FDA clearance for its T2 Biothreat Panel, a direct-from-blood test designed to detect six biothreat pathogens, including anthrax and botulism-causing bacteria, without the need for blood culture. This approval marks a significant advancement in rapid identification of critical biothreat agents.
Bio-Rad and Seegene Form Global Partnership for Molecular Diagnostics
Bio-Rad Laboratories and Seegene, a leading developer of multiplex molecular diagnostics, entered a global partnership to expand access to Seegene's innovative infectious disease tests. This collaboration aims to leverage Bio-Rad's extensive distribution network to broaden the reach of advanced syndromic testing solutions worldwide.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $38.5 Bn |
| Market Size (Forecast) | $72.3 Bn |
| CAGR | 6.5% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 39 Sub-segments |
| Companies Profiled | 19 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included